Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Non-small Cell Lung Carcinoma
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
The purpose of the present trial is to assess if induction concurrent chemoradiotherapy followed by consolidation chemotherapy will improve survival in comparison with the same chemotherapy given as induction followed by…
- Trial name
- NCT00633568
- Testing
- Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel, Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
- Where
- 19 sites in Belgium, France and 2 more
- Volunteers
- 125 people
- Sponsor
- European Lung Cancer Working Party
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer, Carcinoma, Non-Small Cell Lung
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
This study is designed to determine if combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) (2 fractions) for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy…
- Trial name
- NCT04748419
- Testing
- consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Nebraska
NSCLC, Stage III
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
Aim of this phase 2 study is to evaluate the safety and the efficacy of the combination of induction chemotherapy plus durvalumab followed by reduced-dose hypo-fractionated thoracic RT (concurrent with durvalumab) and durvalumab…
- Trial name
- DEDALUS (NCT05128630)
- Testing
- Durvalumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Lung Cancer
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 is a drug used in the measurement of oxygen in tumor tissue.
- Trial name
- NCT00041028
- Testing
- EF5, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Carcinoma, Non-Small-Cell Lung
Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
Currently, there is only limited data available on the functional immune changes after concurrent chemoradiation in NSCLC (non-small cell lung cancer) patients.
- Trial name
- IPON-1 (NCT04432142)
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- Maastricht Radiation Oncology
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01993810
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer
Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The aim of this study is to evaluate if the multi modality treatment pemetrexed combined with cisplatin and radiotherapy can lead to a better tumor control and/or a better side-effect profile in patients with locally advanced…
- Trial name
- PACCORA (NCT00497315)
- Testing
- combination chemotherapy (pemetrexed + cisplatin), thoracic irradiation + pemetrexed
- Where
- 3 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Antwerp
Lung Cancer Stage III
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Primary Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) Evaluate efficacy by progression-free survival (PFS), objective…
- Trial name
- NCT05358691
- Testing
- AN0025
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Lung Cancer
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113386
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 76 sites in United States
- Volunteers
- 19 people
- Sponsor
- Radiation Therapy Oncology Group
Stage III NSCLC
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
- Trial name
- Induction (NCT04287894)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Lung Cancer, Non-small Cell Carcinoma
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiation, followed by consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12…
- Trial name
- NCT04364048
- Testing
- Induction Durvalumab, Chemotherapy, Radiation
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rachel Sanborn
Stage III Non-small Cell Lung Cancer
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves…
- Trial name
- NCT04984148
- Testing
- CT
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
Stage III Non-small Cell Lung Cancer
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR).
- Trial name
- NCT05891080
- Testing
- Toripalimab, JS004, Pemetrexed
- Volunteers
- 124 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Stage III Non-Small Cell Lung Cancer
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.
- Trial name
- NCT00938418
- Testing
- Dose escalated, accelerated, hypofractionated radiotherapy
- Where
- 3 sites in Singapore
- Volunteers
- 43 people
- Sponsor
- National University Hospital, Singapore
Lung Cancer
Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002519
- Testing
- chemotherapy, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Neoplasms
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To classify the 2 study groups, according to the tumoral response. Secondary objectives: To evaluate the percentage of focused control per year. To calculate the time until progression.
- Trial name
- NCT00258739
- Testing
- Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine, Docetaxel + gemcitabine + carboplatin + radiotherapy
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Sanofi
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003111
- Testing
- carboplatin, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
NSCLC, Stage III
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy…
- Trial name
- ESPADURVA (NCT04202809)
- Testing
- Durvalumab
- Where
- 7 sites in Germany
- Volunteers
- 90 people
- Sponsor
- University Hospital, Essen
Carcinoma, Non-Small-Cell Lung
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil
- Trial name
- NCT04948411
- Where
- 4 sites in Brazil
- Volunteers
- 33 people
- Sponsor
- Latin American Cooperative Oncology Group